Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.

Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, Wong KK, Brandstetter K, Wittner B, Ramaswamy S, Classon M, Settleman J.

Cell. 2010 Apr 2;141(1):69-80. doi: 10.1016/j.cell.2010.02.027.

2.

The KDM5 family of histone demethylases as targets in oncology drug discovery.

Rasmussen PB, Staller P.

Epigenomics. 2014 Jun;6(3):277-86. doi: 10.2217/epi.14.14.

PMID:
25111482
3.

Histone-modifying enzymes: regulators of developmental decisions and drivers of human disease.

Butler JS, Koutelou E, Schibler AC, Dent SY.

Epigenomics. 2012 Apr;4(2):163-77. doi: 10.2217/epi.12.3. Review.

4.

A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases.

Luo X, Liu Y, Kubicek S, Myllyharju J, Tumber A, Ng S, Che KH, Podoll J, Heightman TD, Oppermann U, Schreiber SL, Wang X.

J Am Chem Soc. 2011 Jun 22;133(24):9451-6. doi: 10.1021/ja201597b. Epub 2011 May 31.

5.

Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.

Haven B, Heilig E, Donham C, Settles M, Vasilevsky N, Owen K; Reproducibility Project: Cancer Biology; Reproducibility Project Cancer Biology.

Elife. 2016 Feb 23;5. pii: e09462. doi: 10.7554/eLife.09462.

6.

Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.

Kim JS, Lee SC, Min HY, Park KH, Hyun SY, Kwon SJ, Choi SP, Kim WY, Lee HJ, Lee HY.

Cancer Lett. 2015 Jun 1;361(2):197-206. doi: 10.1016/j.canlet.2015.02.038. Epub 2015 Feb 23.

PMID:
25721083
7.

A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth.

Wang L, Chang J, Varghese D, Dellinger M, Kumar S, Best AM, Ruiz J, Bruick R, Peña-Llopis S, Xu J, Babinski DJ, Frantz DE, Brekken RA, Quinn AM, Simeonov A, Easmon J, Martinez ED.

Nat Commun. 2013;4:2035. doi: 10.1038/ncomms3035. Erratum in: Nat Commun. 2013;4:2639.

8.

Epigenetic targets and drug discovery Part 2: Histone demethylation and DNA methylation.

Liu K, Liu Y, Lau JL, Min J.

Pharmacol Ther. 2015 Jul;151:121-40. doi: 10.1016/j.pharmthera.2015.04.001. Epub 2015 Apr 7. Review.

PMID:
25857453
9.

A coding single-nucleotide polymorphism in lysine demethylase KDM4A associates with increased sensitivity to mTOR inhibitors.

Van Rechem C, Black JC, Greninger P, Zhao Y, Donado C, Burrowes PD, Ladd B, Christiani DC, Benes CH, Whetstine JR.

Cancer Discov. 2015 Mar;5(3):245-54. doi: 10.1158/2159-8290.CD-14-1159. Epub 2015 Jan 6.

10.

The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6.

Toyokawa G, Cho HS, Iwai Y, Yoshimatsu M, Takawa M, Hayami S, Maejima K, Shimizu N, Tanaka H, Tsunoda T, Field HI, Kelly JD, Neal DE, Ponder BA, Maehara Y, Nakamura Y, Hamamoto R.

Cancer Prev Res (Phila). 2011 Dec;4(12):2051-61. doi: 10.1158/1940-6207.CAPR-11-0290. Epub 2011 Sep 19.

11.

Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.

Samulitis BK, Pond KW, Pond E, Cress AE, Patel H, Wisner L, Patel C, Dorr RT, Landowski TH.

Cancer Biol Ther. 2015;16(1):43-51. doi: 10.4161/15384047.2014.986967.

12.

Lysine demethylases inhibitors.

Suzuki T, Miyata N.

J Med Chem. 2011 Dec 22;54(24):8236-50. doi: 10.1021/jm201048w. Epub 2011 Oct 7. Review. No abstract available.

PMID:
21955276
13.

SCF(FBXO22) regulates histone H3 lysine 9 and 36 methylation levels by targeting histone demethylase KDM4A for ubiquitin-mediated proteasomal degradation.

Tan MK, Lim HJ, Harper JW.

Mol Cell Biol. 2011 Sep;31(18):3687-99. doi: 10.1128/MCB.05746-11. Epub 2011 Jul 18.

14.

Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.

Gale M, Sayegh J, Cao J, Norcia M, Gareiss P, Hoyer D, Merkel JS, Yan Q.

Oncotarget. 2016 Jun 28;7(26):39931-39944. doi: 10.18632/oncotarget.9539.

15.

Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14.

Li Q, Shi L, Gui B, Yu W, Wang J, Zhang D, Han X, Yao Z, Shang Y.

Cancer Res. 2011 Nov 1;71(21):6899-908. doi: 10.1158/0008-5472.CAN-11-1523. Epub 2011 Sep 21.

16.

A new horizon for epigenetic medicine?

Chen S, Shi Y.

Cell Res. 2013 Mar;23(3):326-8. doi: 10.1038/cr.2012.136. Epub 2012 Sep 18.

17.

KSHV PAN RNA associates with demethylases UTX and JMJD3 to activate lytic replication through a physical interaction with the virus genome.

Rossetto CC, Pari G.

PLoS Pathog. 2012;8(5):e1002680. doi: 10.1371/journal.ppat.1002680. Epub 2012 May 10.

18.

KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.

Chin YW, Han SY.

Expert Opin Ther Pat. 2015 Feb;25(2):135-44. doi: 10.1517/13543776.2014.991310. Epub 2014 Dec 3. Review.

PMID:
25468267
19.

The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation.

Raha D, Wilson TR, Peng J, Peterson D, Yue P, Evangelista M, Wilson C, Merchant M, Settleman J.

Cancer Res. 2014 Jul 1;74(13):3579-90. doi: 10.1158/0008-5472.CAN-13-3456. Epub 2014 May 8.

20.

Coordinated methyl-lysine erasure: structural and functional linkage of a Jumonji demethylase domain and a reader domain.

Upadhyay AK, Horton JR, Zhang X, Cheng X.

Curr Opin Struct Biol. 2011 Dec;21(6):750-60. doi: 10.1016/j.sbi.2011.08.003. Epub 2011 Aug 25.

Supplemental Content

Support Center